News
Discover the latest news from ID SOLUTIONS
ASCO 2024 Congress: meet the ID SOLUTIONS Oncology team!
Meeting between oncology professionals and creating partnerships (…)
Liquid biopsy follow-up: A new era for women treated for advanced breast cancer
Patients with advanced ER+/HER2- breast cancer treated with endocrine therapy are at greater risk of developing resistance mutations in various genes, including Estrogen Receptor 1 (ESR1).
February 4th – WORLD CANCER DAY
ID SOLUTIONS supports and encourages all initiatives in the fight against cancer.
Launch of our new kit: IDESR1
ID SOLUTIONS offers innovative liquid biopsy solutions, and has added
Nos dernières études cliniques
Organisme Promoteur
Organisme Promoteur
Organes
Organes
Date de publication
12/11/2022
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharma cokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) with RGFR or HER2
Organisme Promoteur
Organisme Promoteur
Organes
Organes
Date de publication
12/11/2022
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharma cokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) with RGFR or HER2
Organisme Promoteur
Organisme Promoteur
Organes
Organes
Date de publication
12/11/2022
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharma cokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) with RGFR or HER2
